UChicago Medicine

https://www.uchicagomedicine.org/

 

UChicago Annual Updates from ASH 2019
J

ASH 2019 Updates in Multiple Myeloma: Early Intervention in High Risk Smoldering MM & Daratumumab Based Quadruplet Regimens in Newly Diagnosed MM

By UChicago Annual Updates from ASH 2019 FEATURING Jagoda Jasielec
By UChicago Annual Updates from ASH 2019 FEATURING Jagoda Jasielec
101 views
March 20, 2020
0 Comments
Login to view comments. Click here to Login

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay
Annual Updates from ASH 2019
16:52
UChicago Annual Updates from ASH 2019

Hereditary Hematopoietic Malignancies: What to Look For, and What to…

Feat. M. Drazer
25:56
UChicago Annual Updates from ASH 2019

Inherited Predisposition to Myeloid Hematologic Malignancies: Why Do…

Feat. S. Feurstein
17:22
UChicago Annual Updates from ASH 2019

BCL2 Inhibition in Myeloid Malignancies: Venetoclax + Azacitidine in…

Feat. O. Odenike
12:07
UChicago Annual Updates from ASH 2019

Updates on Myeloid Malignancies: JAK in MF, TGFb Inhibition in MF an…

Feat. O. Odenike
12:13
UChicago Annual Updates from ASH 2019

Highlights from ASH on ALL: Role of AlloSCT in CR1 for Young Adults …

Feat. W. Stock
07:26
UChicago Annual Updates from ASH 2019

Highlight from ASH on ALL: Frontline Therapy in Older Adults & D…

Feat. W. Stock
10:45
UChicago Annual Updates from ASH 2019

Updates on CAR-T Treatment of ALL: Prognosticators of Response, Dual…

Feat. W. Stock
13:28
UChicago Annual Updates from ASH 2019

ASH 2019 Updates in Multiple Myeloma: Early Intervention in High Ris…

Feat. J. Jasielec
16:33
UChicago Annual Updates from ASH 2019

ASH 2019 Updates in R/R Multiple Myeloma: Prolonged PFS with KdD, Ve…

Feat. J. Jasielec
09:30
UChicago Annual Updates from ASH 2019

ASH 2019 Updates on CAR T Cell Therapy in DLBCL: Liso-cel has Favora…

Feat. P. Riedell
05:40
UChicago Annual Updates from ASH 2019

ASH 2019 Updates on CAR T Cell Therapy in Mantle Cell Lymphoma: KTE-…

Feat. P. Riedell
13:18
UChicago Annual Updates from ASH 2019

ASH 2019 Updates on CAR T Cell Therapy in CLL/SLL: Liso-cel Active i…

Feat. P. Riedell
08:12
UChicago Annual Updates from ASH 2019

ASH 2019 Updates on PET Directed Therapy for Early Stage DLBCL

Feat. J. Kline
12:46
UChicago Annual Updates from ASH 2019

ASH 2019 Updates on FL: Obinutuzimab + Lenalidomide in Frontline Set…

Feat. J. Kline
10:07
UChicago Annual Updates from ASH 2019

ASH 2019 Updates on Hodgkin Lymphoma: Frontline Brentuximab + Nivo i…

Feat. J. Kline
15:37
UChicago Annual Updates from ASH 2019

ASH 2019 Updates on Treatment of Young 'Fit' CLL Pts: Impr…

Feat. N. Jain
14:45
UChicago Annual Updates from ASH 2019

ASH 2019 Treatment of Older FCR Ineligible CLL Pts: 5 Years Follow‐u…

Feat. N. Jain
09:43
UChicago Annual Updates from ASH 2019

ASH 2019 Updates in R/R CLL: PFS and OS Benefit with VenR, Associati…

Feat. N. Jain